Oncology Ventures

Oncology Ventures is a New York-based venture fund with a single focus: data-driven digital health and software companies that improve cancer care outcomes. In a venture market full of generalists, the firm has chosen a vertical that is large, complex, and full of structural inefficiency, and built its sourcing, diligence, and value-add around it. The team writes early checks and tends to spend more time inside portfolio companies than a traditional generalist would.

The thesis is narrow by design. Investments concentrate on digital health and healthcare software that touches the cancer care continuum, including clinical decision support, patient navigation, remote monitoring and toxicity management, real-world data and registries, oncology-specific revenue cycle and operations tools, AI applied to imaging or pathology in oncology contexts, and software supporting oncology clinical trials. Therapeutics, devices, and diagnostics are generally outside the core thesis unless paired with a software offering.

Investments are typically Seed and Series A with checks of roughly two hundred fifty thousand to one million dollars. Geographic focus is United States, with selective interest in Canada, the United Kingdom, and Israel. The fund is comfortable participating alongside larger healthcare and digital health VCs, and frequently writes the first or second institutional check in a company.

As a specialist firm, Oncology Ventures runs lean. The team is built around partners and operators with oncology backgrounds, and diligence often includes oncologists and cancer center operators who know the workflow and the buyer. Founders should expect detailed conversations about provider segment, payor strategy, and how the company will navigate the realities of selling into community oncology versus academic centers.

The value proposition is depth in a category where generalists struggle. Portfolio companies can lean on the firm for introductions to oncology-specific buyers, channel partners like GPOs and oncology networks, and clinical advisors who can sharpen evidence strategies. The fund’s specialization also means downstream investors take warm introductions seriously, since pattern recognition in oncology software is rare. The trade-off is that founders should be honest about whether their product is genuinely an oncology company or just one that has cancer customers; specialists tend to push back hard on positioning, and that pressure is part of the value but can feel uncomfortable for early teams. The fit is strongest for founders whose entire wedge is oncology, who have clinical credibility, and who want a small early check from a partner who is unusually informed about the category. For broader digital health companies with oncology as one of several markets, a generalist healthcare VC is usually the better counterparty.